BTAI BioXcel Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BTAI

Price (delayed)

$18.87

Market cap

$550.24M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.64

Enterprise value

$480.49M

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically ...

Highlights
BTAI's revenue has surged by 55% since the previous quarter
The gross profit has soared by 55% from the previous quarter
The equity has dropped by 73% year-on-year and by 31% since the previous quarter
BioXcel Therapeutics's net income has shrunk by 67% YoY and by 13% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.bioxceltherapeutics.com
Peers: OVID

Key stats

What are the main financial stats of BTAI
Market
Shares outstanding
29.16M
Market cap
$550.24M
Enterprise value
$480.49M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.33
Price to sales (P/S)
929.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
827
Earnings
Revenue
$581,000
EBIT
-$175.29M
EBITDA
-$174.96M
Free cash flow
-$155.3M
Per share
EPS
-$6.64
Free cash flow per share
-$5.43
Book value per share
$1.83
Revenue per share
$0.02
TBVPS
$6.29
Balance sheet
Total assets
$180.1M
Total liabilities
$127.1M
Debt
$95.77M
Equity
$53.01M
Working capital
$148.51M
Liquidity
Debt to equity
1.81
Current ratio
6.16
Quick ratio
5.77
Net debt/EBITDA
0.4
Margins
EBITDA margin
-30,113.1%
Gross margin
95%
Net margin
-32,199.5%
Operating margin
-30,872.6%
Efficiency
Return on assets
-85.1%
Return on equity
-177.7%
Return on invested capital
-239.2%
Return on capital employed
-115.8%
Return on sales
-30,169.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BTAI stock price

How has the BioXcel Therapeutics stock price performed over time
Intraday
-2.33%
1 week
-25.18%
1 month
-9.93%
1 year
63.52%
YTD
-12.15%
QTD
1.13%

Financial performance

How have BioXcel Therapeutics's revenue and profit performed over time
Revenue
$581,000
Gross profit
$552,000
Operating income
-$179.37M
Net income
-$187.08M
Gross margin
95%
Net margin
-32,199.5%
BioXcel Therapeutics's net income has shrunk by 67% YoY and by 13% QoQ
The company's operating income has shrunk by 60% YoY and by 12% QoQ
BTAI's revenue has surged by 55% since the previous quarter
The gross profit has soared by 55% from the previous quarter

Growth

What is BioXcel Therapeutics's growth rate over time

Valuation

What is BioXcel Therapeutics stock price valuation
P/E
N/A
P/B
10.33
P/S
929.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
827
BTAI's EPS has dropped by 62% year-on-year and by 12% since the previous quarter
BTAI's price to book (P/B) is 91% higher than its 5-year quarterly average of 5.4 and 81% higher than its last 4 quarters average of 5.7
The equity has dropped by 73% year-on-year and by 31% since the previous quarter
BTAI's revenue has surged by 55% since the previous quarter

Efficiency

How efficient is BioXcel Therapeutics business performance
BioXcel Therapeutics's return on assets has shrunk by 89% YoY and by 17% QoQ
The company's return on equity has shrunk by 51% QoQ
BTAI's return on sales is up by 28% since the previous quarter
BioXcel Therapeutics's ROIC has increased by 21% from the previous quarter

Dividends

What is BTAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BTAI.

Financial health

How did BioXcel Therapeutics financials performed over time
The total assets is 42% more than the total liabilities
BTAI's quick ratio has dropped by 54% year-on-year and by 2.2% since the previous quarter
BTAI's current ratio has plunged by 53% YoY
BTAI's debt is 81% greater than its equity
The equity has dropped by 73% year-on-year and by 31% since the previous quarter
BioXcel Therapeutics's debt to equity has increased by 48% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.